| Chronic Obstructive Airway Disease
Incruse Ellipta vs Trelegy Ellipta
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Incruse Ellipta vs Trelegy Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrelegy Ellipta has a higher rate of injection site reactions vs Incruse Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trelegy Ellipta but not Incruse Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Incruse Ellipta
Trelegy Ellipta
At A Glance
Oral inhalation
Once daily
Long-acting muscarinic antagonist
Oral inhalation
Once daily
ICS/LAMA/LABA
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Chronic Obstructive Airway Disease 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation; use at the same time every day; do not use more than 1 time every 24 hours. No dosage adjustment required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
Chronic Obstructive Airway Disease 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Asthma 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or 200/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Contraindications
- Severe hypersensitivity to milk proteins
- Hypersensitivity to umeclidinium or any of the excipients
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipient
Adverse Reactions
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, cough, arthralgia, pharyngitis, viral upper respiratory tract infection, myalgia, abdominal pain upper, toothache, contusion, tachycardia
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Eye pain, glaucoma, vision blurred, anaphylaxis, angioedema, pruritus, urticaria, dysuria, urinary retention, dysphonia, oropharyngeal pain
Most common (>=1%) Headache, back pain, nasopharyngitis, upper respiratory tract infection, bronchitis, dysgeusia, cough, oropharyngeal pain, diarrhea, influenza, sinusitis, oral candidiasis, arthralgia, dysphonia, pneumonia, urinary tract infection, rhinitis, constipation, gastroenteritis
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, intraocular pressure increase, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, anxiety, dysuria, urinary retention
Pharmacology
Long-acting muscarinic antagonist (LAMA/anticholinergic); competitively and reversibly inhibits M3 receptors at airway smooth muscle to produce bronchodilation lasting longer than 24 hours after once-daily oral inhalation.
TRELEGY ELLIPTA combines fluticasone furoate (ICS), umeclidinium (long-acting muscarinic antagonist), and vilanterol (LABA); fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, umeclidinium produces bronchodilation through M3 muscarinic receptor inhibition, and vilanterol relaxes bronchial smooth muscle through beta2-adrenergic receptor stimulation and increased cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Incruse Ellipta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Trelegy Ellipta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Incruse Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Trelegy Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Incruse Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Trelegy Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Incruse Ellipta.
No savings programs available for Trelegy Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Incruse ElliptaView full Incruse Ellipta profile
Trelegy ElliptaView full Trelegy Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.